Live
- First Impressions and Unboxing of the MacBook Pro M4: A Powerhouse for Professionals and Creators
- China Gears Up for Potential Trade War Amid Trump’s Tariff Threats
- Small Farmers Gain Less by Selling to Supermarkets: Study Reveals
- Why Despite the Controversy, America Is Anticipating the Mike Tyson vs. Jake Paul Fight
- Sanju Samson and Tilak Varma Shine: Record-Breaking Feats in 4th T20I Against South Africa
- India Urges $1.3 Trillion Annual Climate Support for Developing Nations
- Bad air: 106 shuttle buses, 60 extra Metro trips planned to make Delhiites give up cars
- WHO reports declining monkeypox cases in Congo
- CM Attends Kotideepotsavam on Kartika Purnima
- PKL Season 11: Raiding trio of Devank, Ayan, Sandeep help Patna Pirates rout Bengal Warriorz
USFDA make observations on Granules Hyd facility
Yet another Hyderabad based pharma company, Granules India, now gets the USFDA observations.
Hyderabad: Yet another Hyderabad based pharma company, Granules India, now gets the USFDA observations. The Granules India, which has informed the bourses, has received three observations from the USFDA for its Jeedimetla facility in Hyderabad during a recent inspection.
USFDA had recently completed inspection of company's two facilities, one at Vizag in Andhra Pradesh and another at Jeedimetla in Telangana, Granules India said in a regulatory filing. "There are no observations for Vizag facility and three observations for Jeedimetla facility. The company will respond to the observations in 15 business days", the release added.
The city-based firm serves customers in over 60 countries and has manufacturing footprint in India and China. It has three facilities in Hyderabad and one in Jingmen, China. A fifth factory is under construction in Vizag through its JV company Granules OmniChem. Granules India shares today ended at Rs 157.65 apiece on the BSE, up 2.17 per cent from the previous close.
